Anne Li August 26th, 2017 email@example.com
The U.S. Food and Drug Administration on August 17th, approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
See original article at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm572131.htm